Diabetes and the Abdominal Aortic Aneurysm

European Journal of Vascular and Endovascular Surgery

Volumn 39, Issue 2, 2010, Pages 200-207

  Shantikumar, S ^a   Ajjan, R ^a   Porter, K E ^a   Scott, D J A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; Diabetes; Glycaemia; Pathogenesis

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ROSIGLITAZONE; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ANEURYSM RUPTURE; ANEURYSM SURGERY; AORTA ANEURYSM; AORTA WALL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; FIBRINOLYSIS; HUMAN; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

AORTIC ANEURYSM, ABDOMINAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; PREVALENCE;

EID: 76549127315     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.10.014     Document Type: Review

References (64)

1. Forouhi N.G., Merrick D., Goyder E., Ferguson B.A., Abbas J., Lachowycz K., et al. Diabetes prevalence in England, 2001 - estimates from an epidemiological model. Diabet Med 23 2 (2006) 189-197
2. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 5 (2004) 1047-1053
3. Ubink-Veltmaat L.J., Bilo H.J., Groenier K.H., Houweling S.T., Rischen R.O., and Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 18 8 (2003) 793-800
4. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., et al. Diabetes trends in the U.S.: 1990-1998. Diabet Care 23 9 (2000) 1278-1283
5. Sorensen T.I. The changing lifestyle in the world. Body weight and what else?. Diabet Care 23 Suppl. 2 (2000) B1-B4
6. Bengtsson H., Bergqvist D., and Sternby N.H. Increasing prevalence of abdominal aortic aneurysms. A necropsy study. Eur J Surg 158 1 (1992) 19-23
7. Silverberg E., Boring C.C., and Squires T.S. Cancer statistics, 1990. CA Cancer J Clin 40 1 (1990) 9-26
8. Simoni G., Pastorino C., Perrone R., Ardia A., Gianrossi R., Decian F., et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg 10 2 (1995) 207-210
9. Kanagasabay R., Gajraj H., Pointon L., and Scott R.A. Co-morbidity in patients with abdominal aortic aneurysm. J Med Screen 3 4 (1996) 208-210
10. LaMorte W.W., Scott T.E., and Menzoian J.O. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. J Vasc Surg 21 3 (1995) 422-431
11. Mattes E., Davis T.M., Yang D., Ridley D., Lund H., and Norman P.E. Prevalence of abdominal aortic aneurysms in men with diabetes. Med J Aust 166 12 (1997) 630-633
12. Lederle F.A., Johnson G.R., Wilson S.E., Chute E.P., Littooy F.N., Bandyk D., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 126 6 (1997) 441-449
13. Lederle F.A., Johnson G.R., Wilson S.E., Chute E.P., Hye R.J., Makaroun M.S., et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 160 10 (2000) 1425-1430
14. Blanchard J.F., Armenian H.K., and Friesen P.P. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol 151 6 (2000) 575-583
15. Kang S.S., Littooy F.N., Gupta S.R., Johnson G.R., Fisher S.G., Cote W.L., et al. Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. Surgery 126 4 (1999) 687-691 discussion, pp. 682-91
16. Karanjia P.N., Madden K.P., and Lobner S. Coexistence of abdominal aortic aneurysm in patients with carotid stenosis. Stroke 25 3 (1994) 627-630
17. Shteinberg D., Halak M., Shapiro S., Kinarty A., Sobol E., Lahat N., et al. Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response. Eur J Vasc Endovasc Surg 20 5 (2000) 462-465
18. Jamrozik K., Norman P.E., Spencer C.A., Parsons R.W., Tuohy R., Lawrence-Brown M.M., et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust 173 7 (2000) 345-350
19. Le M.T., Jamrozik K., Davis T.M., and Norman P.E. Negative association between infra-renal aortic diameter and glycaemia: the health in men study. Eur J Vasc Endovasc Surg 33 5 (2007) 599-604
20. Lederle F.A., Larson J.C., Margolis K.L., Allison M.A., Freiberg M.S., Cochrane B.B., et al. Abdominal aortic aneurysm events in the women's health initiative: cohort study. BMJ 337 (2008) a1724
21. Blanchard J.F. Epidemiology of abdominal aortic aneurysms. Epidemiol Rev 21 2 (1999) 207-221
22. Patel M.I., Hardman D.T., Fisher C.M., and Appleberg M. Current views on the pathogenesis of abdominal aortic aneurysms. J Am Coll Surg 181 4 (1995) 371-382
23. Norman P.E., Davis T.M., Le M.T., and Golledge J. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res 48 3 (2007) 125-131
24. Sakalihasan N., Heyeres A., Nusgens B.V., Limet R., and Lapiere C.M. Modifications of the extracellular matrix of aneurysmal abdominal aortas as a function of their size. Eur J Vasc Surg 7 6 (1993) 633-637
25. Freestone T., Turner R.J., Coady A., Higman D.J., Greenhalgh R.M., and Powell J.T. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15 8 (1995) 1145-1151
26. Goodall S., Crowther M., Hemingway D.M., Bell P.R., and Thompson M.M. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 104 3 (2001) 304-309
27. McMillan W.D., Tamarina N.A., Cipollone M., Johnson D.A., Parker M.A., and Pearce W.H. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 96 7 (1997) 2228-2232
28. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110 5 (2002) 625-632
29. Pearce W.H., and Shively V.P. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann N Y Acad Sci 1085 (2006) 117-132
30. Golledge J., Karan M., Moran C.S., Muller J., Clancy P., Dear A.E., et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 29 5 (2008) 665-672
31. Brady A.R., Thompson S.G., Fowkes F.G., Greenhalgh R.M., and Powell J.T. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110 1 (2004) 16-21
32. Jones S.C., Saunders H.J., and Pollock C.A. High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabet Med 16 11 (1999) 932-938
33. Astrand H., Ryden-Ahlgren A., Sundkvist G., Sandgren T., and Lanne T. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg 33 5 (2007) 592-598
34. Portik-Dobos V., Anstadt M.P., Hutchinson J., Bannan M., and Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51 10 (2002) 3063-3068
35. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21 1 (2003) 3-12
36. Sakata N., Meng J., and Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 7 3 (2000) 169-176
37. Gao L., Kang L., Chen Q., Chen C., Xu B., and Jiang S. Advanced glycation end products inhibit production and activity of matrix metalloproteinase-2 in human umbilical vein endothelial cells. J Int Med Res 35 5 (2007) 709-715
38. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108 9 (2003) 1070-1077
39. Norman P.E., Davis W.A., Coughlan M.T., Forbes J.M., Golledge J., and Davis T.M. Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: health in men study. J Vasc Surg 50 3 (2009) 626-631
40. Madi H.A., Riches K., Warburton P., O'Regan D.J., Turner N.A., and Porter K.E. Inherent differences in morphology, proliferation and migration in saphenous vein smooth muscle cells cultured from non-diabetic and type 2 diabetic patients. Am J Physiol Cell Physiol (2009)
41. van Heerebeek L., Hamdani N., Handoko M.L., Falcao-Pires I., Musters R.J., Kupreishvili K., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 1 (2008) 43-51
42. Ceriello A., Ihnat M.A., and Thorpe J.E. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 94 2 (2009) 410-415
43. Ahimastos A.A., Natoli A.K., Lawler A., Blombery P.A., and Kingwell B.A. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 45 6 (2005) 1194-1199
44. Liao S., Miralles M., Kelley B.J., Curci J.A., Borhani M., and Thompson R.W. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 33 5 (2001) 1057-1064
45. Hackam D.G., Thiruchelvam D., and Redelmeier D.A. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 368 9536 (2006) 659-665
46. Evans J., Powell J.T., Schwalbe E., Loftus I.M., and Thompson M.M. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 34 3 (2007) 302-303
47. Li L., Mamputu J.C., Wiernsperger N., and Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 54 7 (2005) 2227-2234
48. Jones A., Deb R., Torsney E., Howe F., Dunkley M., Gnaneswaran Y., et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 119 24 (2009) 3125-3132
49. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 6 (2002) 679-684
50. Sorice G.P., and Folli F. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). Med Hypotheses 73 4 (2009) 614-618
51. Swedenborg J., and Eriksson P. The intraluminal thrombus as a source of proteolytic activity. Ann N Y Acad Sci 1085 (2006) 133-138
52. Wolf Y.G., Thomas W.S., Brennan F.J., Goff W.G., Sise M.J., and Bernstein E.F. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg 20 4 (1994) 529-535 discussion, p. 528-35
53. Sakalihasan N., Delvenne P., Nusgens B.V., Limet R., and Lapiere C.M. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 24 1 (1996) 127-133
54. Fontaine V., Jacob M.P., Houard X., Rossignol P., Plissonnier D., Angles-Cano E., et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 161 5 (2002) 1701-1710
55. Panek B., Gacko M., and Palka J. Metalloproteinases, insulin-like growth factor-I and its binding proteins in aortic aneurysm. Int J Exp Pathol 85 3 (2004) 159-164
56. Kazi M., Thyberg J., Religa P., Roy J., Eriksson P., Hedin U., et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 38 6 (2003) 1283-1292
57. Vorp D.A., Lee P.C., Wang D.H., Makaroun M.S., Nemoto E.M., Ogawa S., et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 34 2 (2001) 291-299
58. Dunn E.J., Ariens R.A., and Grant P.J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48 6 (2005) 1198-1206
59. Touat Z., Ollivier V., Dai J., Huisse M.G., Bezeaud A., Sebbag U., et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 168 3 (2006) 1022-1030
60. Houard X., Rouzet F., Touat Z., Philippe M., Dominguez M., Fontaine V., et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol 212 1 (2007) 20-28
61. Murphy G., Atkinson S., Ward R., Gavrilovic J., and Reynolds J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 667 (1992) 1-12
62. Allaire E., Hasenstab D., Kenagy R.D., Starcher B., Clowes M.M., and Clowes A.W. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 98 3 (1998) 249-255
63. Rossaak J.I., Van Rij A.M., Jones G.T., and Harris E.L. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J Vasc Surg 31 5 (2000) 1026-1032
64. Festa A., D'Agostino Jr. R., Mykkanen L., Tracy R.P., Zaccaro D.J., Hales C.N., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19 3 (1999) 562-568